Topical Collection "MicroRNAs in Cancer: From Molecular Mechanisms to Applications in Diagnostic and Therapeutic Opportunities"
Share This Topical Collection
Editor
Topical Collection Information
Dear Colleagues,
MicroRNAs (miRNAs) are small noncoding RNAs that play important roles in gene regulation by repressing translation or directing sequence-specific degradation of complementary mRNA or inducing gene expression via binding to promoter sequences, therefore regulating cell growth and development. MiRNAs are also known to regulate tumor progression. miRNAs have gained significant attention over the last decade due to their great potential in the development of the next-generation approaches to fight against cancer.
This Topical Collection of Cells invites investigators to contribute original research articles, reviews, and perspectives focusing on recent advances in cancer research with miRNAs (e.g., therapy and biomarkers for diagnosis). Manuscripts solely describing bioinformatics or in silico computational analysis of public databases that are not accompanied by biological validation will not be considered. We are looking for contributions that primarily focus on the use of miRNAs for various types of cancer, including rarer varieties.
Dr. Tohru Yamada
Collection Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the collection website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript.
The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs).
Submitted papers should be well formatted and use good English. Authors may use MDPI's
English editing service prior to publication or during author revisions.
Keywords
- oncogenes
- tumor suppressors
- circulating miRNA
- targeting delivery
- chemical modifications
- cargo molecule conjugations
Published Papers (3 papers)
2023
Open AccessArticle
MicroRNA-Based Discovery of Biomarkers, Therapeutic Targets, and Repositioning Drugs for Breast Cancer
Cited by 3 | Viewed by 1093
Abstract
Breast cancer treatment can be improved with biomarkers for early detection and individualized therapy. A set of 86 microRNAs (miRNAs) were identified to separate breast cancer tumors from normal breast tissues (
n = 52) with an overall accuracy of 90.4%. Six miRNAs
[...] Read more.
Breast cancer treatment can be improved with biomarkers for early detection and individualized therapy. A set of 86 microRNAs (miRNAs) were identified to separate breast cancer tumors from normal breast tissues (
n = 52) with an overall accuracy of 90.4%. Six miRNAs had concordant expression in both tumors and breast cancer patient blood samples compared with the normal control samples. Twelve miRNAs showed concordant expression in tumors vs. normal breast tissues and patient survival (
n = 1093), with seven as potential tumor suppressors and five as potential oncomiRs. From experimentally validated target genes of these 86 miRNAs, pan-sensitive and pan-resistant genes with concordant mRNA and protein expression associated with in-vitro drug response to 19 NCCN-recommended breast cancer drugs were selected. Combined with in-vitro proliferation assays using CRISPR-Cas9/RNAi and patient survival analysis, MEK inhibitors PD19830 and BRD-K12244279, pilocarpine, and tremorine were discovered as potential new drug options for treating breast cancer. Multi-omics biomarkers of response to the discovered drugs were identified using human breast cancer cell lines. This study presented an artificial intelligence pipeline of miRNA-based discovery of biomarkers, therapeutic targets, and repositioning drugs that can be applied to many cancer types.
Full article
►▼
Show Figures
Open AccessReview
MicroRNAs in Tumor Endothelial Cells: Regulation, Function and Therapeutic Applications
Cited by 2 | Viewed by 1085
Abstract
Tumor endothelial cells (TECs) are key stromal components of the tumor microenvironment, and are essential for tumor angiogenesis, growth and metastasis. Accumulating evidence has shown that small single-stranded non-coding microRNAs (miRNAs) act as powerful endogenous regulators of TEC function and blood vessel formation.
[...] Read more.
Tumor endothelial cells (TECs) are key stromal components of the tumor microenvironment, and are essential for tumor angiogenesis, growth and metastasis. Accumulating evidence has shown that small single-stranded non-coding microRNAs (miRNAs) act as powerful endogenous regulators of TEC function and blood vessel formation. This systematic review provides an up-to-date overview of these endothelial miRNAs. Their expression is mainly regulated by hypoxia, pro-angiogenic factors, gap junctions and extracellular vesicles, as well as long non-coding RNAs and circular RNAs. In preclinical studies, they have been shown to modulate diverse fundamental angiogenesis-related signaling pathways and proteins, including the vascular endothelial growth factor (VEGF)/VEGF receptor (VEGFR) pathway; the rat sarcoma virus (Ras)/rapidly accelerated fibrosarcoma (Raf)/mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) pathway; the phosphoinositide 3-kinase (PI3K)/AKT pathway; and the transforming growth factor (TGF)-β/TGF-β receptor (TGFBR) pathway, as well as krüppel-like factors (KLFs), suppressor of cytokine signaling (SOCS) and metalloproteinases (MMPs). Accordingly, endothelial miRNAs represent promising targets for future anti-angiogenic cancer therapy. To achieve this, it will be necessary to further unravel the regulatory and functional networks of endothelial miRNAs and to develop safe and efficient TEC-specific miRNA delivery technologies.
Full article
►▼
Show Figures
Open AccessReview
Identification of Exo-miRNAs: A Summary of the Efforts in Translational Studies Involving Triple-Negative Breast Cancer
Viewed by 1319
Abstract
Triple-negative breast cancer (TNBC) accounts for about 10–15% of all breast cancers (BC) in the US and its diagnosis is associated with poor survival outcomes. A better understanding of the disease etiology is crucial to identify target treatment options to improve patient outcomes.
[...] Read more.
Triple-negative breast cancer (TNBC) accounts for about 10–15% of all breast cancers (BC) in the US and its diagnosis is associated with poor survival outcomes. A better understanding of the disease etiology is crucial to identify target treatment options to improve patient outcomes. The role of exo-miRNAs in TNBC has been studied for more than two decades. Although some studies have identified exo-miR candidates in TNBC using clinical samples, consensus regarding exo-miR candidates has not been achieved. The purpose of this review is to gather information regarding exo-miR candidates reported in TNBC translational studies along with the techniques used to isolate and validate the potential targets. The techniques suggested in this review are based on the use of commercially available materials for research and clinical laboratories. We expect that the information included in this review can add additional value to the recent efforts in the development of a liquid biopsy to identify TNBC cases and further improve their survival outcomes.
Full article
►▼
Show Figures
Planned Papers
The below list represents only planned manuscripts. Some of these
manuscripts have not been received by the Editorial Office yet. Papers
submitted to MDPI journals are subject to peer-review.
Title: miR181 - a much ignored miR in HCC
Authors: Geoff McCaughan
Affiliation: University of Sydney, Sydney, Australia
Title: micro-RNAs as diagnostic tool of colon cancer
Authors: Younghwa Song
Affiliation: Stony Brook Medicine, Stony Brook, NY, USA
Title: MicroRNAs in peripheral T-cell Lymphoma pathogenesis
Authors: Dylan Jochum, Javeed Iqbal et al
Affiliation: University of Nebraska Medical Center, Omaha, NE, USA
Title: Clinical relevance and interplay of miRNAs in influencing GBM treatment and prognosis
Authors: Andrea Cardia 1, Samantha Epistolio 2, Ismail Zaed 1, Giulia Dazio 2, Nora Sahnane 3, Roberta Cerutti 3, Debora Cipriani 1, Jessica Barizzi 2, Paolo Spina 2, Federico Mattia Stefanini 4, Michele Cerat
Affiliation: 1. Service of Neurosurgery, Neurocenter of the Southern Switzerland, Regional Hospital of Lugano, Ente Ospedaliero Cantonale (EOC), 6900 Lugano, Switzerland
2. Laboratory of Molecular Pathology, Institute of Pathology, Ente Ospedaliero Cantonale (EOC),
6900 Locarno, Switzerland
3. Unit of Pathology, Department of Medicine and Surgery, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy
4. Department of Environmental Science and Policy, Faculty of Science and Technology-ESP, University of Milan, 20122 Milan, Italy
5. Division of Neurological Surgery, Department of Biotechnology and Life Sciences, University of Insubria, ASST Sette Laghi, 21100 Varese, Italy
6. Radiation Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale (EOC), 6501 Bellinzona, Switzerland
7. Faculty of Medicine, University of Southern Switzerland, 6900 Lugano, Switzerland
Title: MicroRNA-122 inhibits colon cancer cell proliferation and migration by directly regulating MTDH protein
Authors: Surajit Pathak; Xiao Feng Sun
Affiliation: Linkoping University, Sweden
